Aiosyn Mitosis Breast: Mitotic figure counting

How does it compare to standard counting?

The algorithm automatically detects mitotic figures before the case is reviewed. When the WSI is opened, all identified mitoses are highlighted, helping pathologists quickly locate high mitotic activity areas and assist in the count. With Aiosyn Mitosis Breast, pathologists can review the algorithm’s output instead of manually identifying mitoses, reducing evaluation time by up to 60%.

Does the tool support hotspot detection?

Aiosyn Mitosis Breast provides the coordinates and highlights the mitotic figures. This data allows pathology viewers to display mitotic activity, assisting pathologists in identifying areas of high mitotic density. This supports both hotspot detection and accurate counting of mitotic figures. The specific visualization features (heatmaps, squares, etc.) for these high-activity areas vary by the viewer. We are also working on integrating a hotspot detection feature into the clinical version, which is currently only available in Aiosyn Mitosis Research.

What data and information are required to conduct a trial period?

You can request a demonstration of Aiosyn Mitosis Breast very easily. First, you upload a few whole-slide images to our secure online platform. Then, we apply the solution to detect mitotic figures throughout the image. Finally, we give you access to our online viewer where you can examine the product’s detections together with your images.

What are the IT requirements for integrating Aiosyn Mitosis Breast into our existing infrastructure?

We are a flexible provider of AI-powered solutions, and can accommodate most setups, with two common deployment options as follows. First, performing the integration via an existing marketplace, for example: Sectra Amplifier Marketplace, Paige AppLabTM, PathAI AISight, Proscia, etc. We work with most manufacturers to bring our products to your lab with ease. Second, integrating directly with your IMS or custom system via simple HTTP(S) API. In this case, we require that your system is able to send us notifications when a new image is available for processing, and later displaying the detections of the product (mitotic figures). Both deployment options are available on-premise (installed in your own hardware inside your network), or in the cloud (we use tier-1 infrastructure from AWS and Azure).

How does this solution differentiate itself from other AI solutions available on the market?

Aiosyn Mitosis Breast is the first AI-powered mitosis detection solution to achieve CE mark certification under IVDR. The application went through a rigorous validation and multi-center clinical performance study which demonstrated significant improvements in both efficiency and consistency among 28 pathologists across 9 countries when using it. Over 90% of surveyed pathologists who tried Aiosyn Mitosis Breast would like to use the algorithm in their daily practice. In addition, the solution is modular and can be integrated into existing workflows, minimizing investment and disruption of current processes.

What is the scaling capability for handling large cohorts of slides?

For large volumes, Aiosyn Mitosis Breast computing resources can be deployed in the cloud. This has the benefit of providing virtually unlimited scaling capabilities. When needed, extra hardware resources can be invoked to process a large number of slides in parallel, substantially reducing turnaround time. These resources are discarded after the workload is completed, limiting processing costs.

Is the algorithm compliant with GDPR and other data privacy regulations?

Yes, Aiosyn Mitosis Breast is compliant with GDPR and other standard regulations.

What are the available pricing models? Is there an option for per-slide pricing or is it subscription-based?

We establish the pricing models based on your needs and preferences. Both subscriptions and per-slide pricing are available.